Tau imaging probe

Patent metadata

Field	Value
Publication number	US-9701637-B2
Application number	US-201615168604-A
Country	US
Kind code	B2
Filing date	May 31, 2016
Priority date	Oct 29, 2010
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

An object of the present invention is to provide a probe for imaging a β-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity.
According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R a and R b are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.

First claim

What is claimed is:

1. A method of diagnosing a conformational disease in a subject, which comprises administering a labelled compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to the subject, wherein said compound of formula (I) has the following structure:

wherein
A is

R 1 is halogen, a —C(═O)-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from NR a R b , halogen and a hydroxy group), a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), a —O-lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group), or

in which
R 4 and R 5 each independently represents hydrogen, a lower alkyl group or a cycloalkyl group, or R 4 , R 5 and the nitrogen atom to which they are attached are taken together to form a 3- to 8-membered nitrogen-containing aliphatic ring (one or more carbon atoms constituting the nitrogen-containing aliphatic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group),
or R 4 and the nitrogen atom to which it is attached are taken together with ring A to form a 8- to 16-membered nitrogen-containing fused bicyclic ring (one or more carbon atoms constituting the nitrogen-containing fused bicyclic ring may be substituted with a nitrogen atom, a sulfur atom or an oxygen atom, and when a carbon atom is substituted with a nitrogen atom, the nitrogen atom may be substituted with a lower alkyl group) and R 5 represents hydrogen, a lower alkyl group or a cycloalkyl group,
in which the line, that the dotted line intersects, means a bond of the above general formula to the other structural moiety,
R 2 or R 3 each independently represents halogen, OH, COOH, SO 3 H, NO 2 , SH, NR a R b , a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group) or a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group),
ring A is unsubstituted, or substituted with R 6 (in which R 6 is one or more substituents selected independently from halogen, OH, COOH, SO 3 H, NO 2 , SH, NR a R b , a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group) and a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group,
R a and R b each independently represents hydrogen or a lower alkyl group (the alkyl group each independently may be substituted with one or more substituents selected from halogen and a hydroxy group),
m is an integer of 0 to 4,
n is an integer of 0 to 4,
wherein at least one of R 2 , R 3 and R 6 is a —O-lower alkyl group substituted with one hydroxy group and one halogen,
wherein said conformational disease is a tauopathy.

2. The method according to claim 1 , wherein for said compound of formula (I) R 1 is halogen, a —C(═O)-lower alkyl group (the alkyl group each independently may be substituted with NH 2 ), a lower alkyl group (the alkyl group each independently may be substituted with a hydroxy group), —O-lower alkyl group, or

in which
R 4 and R 5 each independently represents hydrogen or a lower alkyl group.

3. The method according to claim 1 , wherein for said compound of formula (I) at least one of R 2 , R 3 and R 6 is represented by:

4. The method according to claim 1 , wherein for said compound of formula (I) at least one of R 2 , R 3 and R 6 is NR a R b , and R a and R b each independently represents hydrogen or an unsubstituted lower alkyl group.

5. The method according to claim 1 , wherein for said compound of formula (I) the label is a radioactive nuclide.

6. The method according to claim 5 , wherein the label is a positron emitting nuclide.

7. The method according to claim 6 , wherein the positron emitting nuclide is selected from the group consisting of 11 C, 13 N, 15 O, 18 F, 35m Cl, 76 Br, 45 Ti, 48 V, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 89 Zr, 94m Tc and 124 I.

8. The method according to claim 7 , wherein the positron emitting nuclide is 11 C or 18 F.

9. The method according to claim 1 , wherein said compound of formula (I) is a labeled compound of the formula (I″):

wherein
A is

R 1 is

in which R 4 and R 5 each independently represents hydrogen, a lower alkyl group,
R 2 or R 3 each independently represents a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group),
ring A is unsubstituted, or substituted with R 6 (in which R 6 is one or more substituents selected independently from a —O-lower alkyl group (the alkyl group each independently may be substituted with at least two substituents selected from halogen and a hydroxy group)),
m is an integer of 0 to 4,
n is an integer of 0 to 4,
wherein R 2 , R 3 and R 6 each represents a —O-lower alkyl group substituted with one hydroxy group and one halogen.

10. The method according to claim 9 , wherein said compound of formula I″ is selected from:

11. The method according to claim 9 , wherein said compound of formula I″ is selected from:

12. The method according to claim 9 , wherein for said compound of formula (I″) the label is a radioactive nuclide.

13. The method according to claim 12 wherein the label is a positron emitting nuclide.

14. The method according to claim 13 , wherein the positron emitting nuclide is selected from the group consisting of 11 C, 13 N, 15 O, 18 F, 35m Cl, 76 Br, 45 Ti, 48 V, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 89 Zr, 94m Tc and 124 I.

15. The method according to claim 14 , wherein the positron emitting nuclide is 11 C or 18 F.

16. The method according to claim 15 , wherein said compound of formula I″ is selected from:

17. The method accord

Assignees

• Ge Healthcare Ltd

Inventors

• Kudo Yukitsuka
• Furumoto Shozo
• Okamura Nobuyuki

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• C07D215/40

  attached in position 8 · CPC title

• C07D215/38

  Nitrogen atoms (nitro radicals C07D215/18) · CPC title